<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Transgender men: Evaluation and management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Transgender men: Evaluation and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Transgender men: Evaluation and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vin Tangpricha, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joshua D Safer, MD, FACP, FACE</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alvin M Matsumoto, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2605066997"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The terms transgender and gender incongruence describe a situation where an individual's gender identity differs from external sexual anatomy at birth. Health care providers should be familiar with commonly used terms  (<a class="graphic graphic_table graphicRef86993" href="/z/d/graphic/86993.html" rel="external">table 1</a>). Gender identity-affirming care, for those who desire, can include hormone therapy and affirming surgeries as well as other procedures such as hair removal or speech therapy [<a href="#rid1">1-7</a>].</p><p>This topic will use the term transgender in the broadest sense to include any person with incongruence between gender identity and external sexual anatomy at birth. The evaluation and management of transgender men are discussed here. The evaluation and management of transgender women, the primary care of the transgender adult, and gender diversity in children and adolescents are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/82964.html" rel="external">"Primary care of transgender individuals"</a> and  <a class="medical medical_review" href="/z/d/html/83665.html" rel="external">"Gender development and clinical presentation of gender diversity in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/86771.html" rel="external">"Management of transgender and gender-diverse children and adolescents"</a>.)</p><p class="headingAnchor" id="H56295935"><span class="h1">STANDARDS OF CARE</span><span class="headingEndMark"> — </span>Several large medical professional organizations have issued guidelines to assist providers in the care of transgender individuals (the World Professional Association for Transgender Health [WPATH] [<a href="#rid8">8</a>], the Endocrine Society [<a href="#rid9">9</a>], the American College of Obstetricians and Gynecologists [ACOG] [<a href="#rid10">10</a>]).</p><p>The Endocrine Society has released updated guidelines for the treatment of gender dysphoria/gender incongruence [<a href="#rid9">9</a>]. The new guidelines replace the term "transsexual" with "gender dysphoria" or "gender incongruence" and specify detailed professional qualifications for clinicians who diagnose, assess, or treat individuals with gender dysphoria/gender incongruence. Specifically, they now suggest that decisions regarding social transition for prepubertal youth be made in conjunction with a mental health or similarly experienced professional. They continue to recommend the management and monitoring of transgender adolescents and adults by a multidisciplinary team, as well as counseling patients about the time course of hormone-induced physical changes and options for fertility preservation. We agree with the updated guidelines  (<a class="graphic graphic_table graphicRef69460" href="/z/d/graphic/69460.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H2961289020"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>The following considerations are similar for transgender men and women and are discussed in detail in the topic on transgender women.</p><p class="bulletIndent1"><span class="glyph">●</span>Epidemiology (see  <a class="medical medical_review" href="/z/d/html/7456.html" rel="external">"Transgender women: Evaluation and management", section on 'Epidemiology'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Pathophysiology (see  <a class="medical medical_review" href="/z/d/html/7456.html" rel="external">"Transgender women: Evaluation and management"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Initial presentation (see  <a class="medical medical_review" href="/z/d/html/7456.html" rel="external">"Transgender women: Evaluation and management"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Initial assessment (see  <a class="medical medical_review" href="/z/d/html/7456.html" rel="external">"Transgender women: Evaluation and management"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Counseling before treatment (see  <a class="medical medical_review" href="/z/d/html/7456.html" rel="external">"Transgender women: Evaluation and management"</a>)</p><p></p><p class="headingAnchor" id="H3781355876"><span class="h1">EVALUATION AND DIAGNOSIS</span></p><p class="headingAnchor" id="H4256142598"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>The current criteria for gender incongruence include:</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent incongruence between gender identity and external sexual anatomy at birth</p><p class="bulletIndent1"><span class="glyph">●</span>The absence of a confounding mental disorder or other abnormality</p><p></p><p>The diagnosis of gender incongruence must be made before considering transgender hormone and surgical therapy [<a href="#rid11">11</a>]. Such diagnosis should include screening for confounding mental health concerns.</p><p>In addition, it is essential to identify any medical and/or psychiatric diagnoses that may require treatment before considering hormone therapy [<a href="#rid11">11,12</a>].</p><p>Presently, most cases of transgender identity are diagnosed in adulthood, but increasingly, children and adolescents with gender dysphoria present for diagnosis and treatment.</p><p>The clinical presentation of gender diversity in children is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/83665.html" rel="external">"Gender development and clinical presentation of gender diversity in children and adolescents"</a>.)</p><p class="headingAnchor" id="H4127247283"><span class="h2">Gender dysphoria</span><span class="headingEndMark"> — </span>Patients also may be diagnosed with gender dysphoria, which is defined as the discomfort arising in some individuals from the incongruence between their gender identities and their external sexual anatomy at birth.</p><p>The diagnosis of gender dysphoria is generally done by a mental health professional; however, other health care professionals who have the appropriate experience and training can also diagnose gender dysphoria. Mental health providers typically use the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) to make a diagnosis [<a href="#rid13">13</a>]. Core components of the DSM-5 diagnosis of gender dysphoria include longstanding discomfort with the incongruence between gender identity and external sexual anatomy at birth along with interference with social, school, or other areas of function [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H2395840128"><span class="h1">HORMONAL THERAPY</span></p><p class="headingAnchor" id="H4223768816"><span class="h2">Transgender men (female-to-male, FTM)</span></p><p class="headingAnchor" id="H3878565536"><span class="h3">Goals</span><span class="headingEndMark"> — </span>The usual aim of transgender hormone therapy is to induce physical changes to match gender identity [<a href="#rid14">14</a>]. The treatment goal is to maintain hormone levels in the normal physiological range for the target gender. Some individuals may identify as nonbinary (eg, having both masculine and feminine identity attributes). While hypogonadism carries risk to bone health and should be addressed, both male and female hormone patterns, along with the entire continuum in between, can be safe.</p><p>Historically, some transgender individuals self-medicated with hormones for a variety of reasons, including fear of rejection by health care providers, delays in initiation of hormone therapy, and the cost of undergoing treatment. Therefore, there should be careful assessment for self-medication, both past and current [<a href="#rid15">15</a>].</p><p>In transgender men, the typical goal is to stop menses and induce virilization, including a male pattern of sexual and facial hair, change in voice, and male physical contours. The principal hormonal treatment is a <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> preparation.</p><p class="headingAnchor" id="H2828918545"><span class="h3">Criteria for starting</span><span class="headingEndMark"> — </span>Criteria for starting hormone therapy include [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent, well-documented gender dysphoria/gender incongruence</p><p class="bulletIndent1"><span class="glyph">●</span>Capacity to make a well-informed decision</p><p class="bulletIndent1"><span class="glyph">●</span>Relevant medical or mental health issues are well controlled</p><p></p><p class="headingAnchor" id="H4129328570"><span class="h3">Testosterone therapy</span><span class="headingEndMark"> — </span>There are many available <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> preparations and routes of administration including injectables, gels, and buccal tablets. We suggest either testosterone esters (administered intramuscularly or subcutaneously) or testosterone gels, depending upon patient preference. However, higher testosterone levels are more easily achieved with parenteral therapy  (<a class="graphic graphic_table graphicRef69460" href="/z/d/graphic/69460.html" rel="external">table 2</a>).</p><p>It is common to use 50 to 100 mg of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> enanthate or testosterone cypionate weekly or 200 mg every two weeks. Route of administration can be intramuscular or subcutaneous with similar effects. Although the subcutaneous route is not approved in the United States by the US Food and Drug Administration (FDA), it appears to be effective and well tolerated [<a href="#rid16">16-18</a>]. In one report of 22 patients who had tried both the intramuscular and subcutaneous route, all preferred subcutaneous administration [<a href="#rid18">18</a>].</p><p>With parenteral <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy, serum testosterone is typically measured midway between injections. However, some clinicians measure serum testosterone 24 hours after injection and again just before the subsequent injection. Some clinicians start with lower doses of testosterone because transgender men are often smaller than average men in size. The goal remains to achieve normal male levels and that can be done as quickly as practical.</p><p><a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> gel (1% or 1.6%, 2.5 to 10 g/day) may also be used [<a href="#rid11">11</a>], but virilization might be slower if lower serum testosterone concentrations are achieved than with testosterone injection. Some clinicians switch to gels once initial virilization is complete. This may help to avoid supraphysiologic testosterone concentrations [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Is the testosterone dose therapeutic?'</a>.)</p><p class="headingAnchor" id="H2064991012"><span class="h4">Masculinizing effects</span><span class="headingEndMark"> — </span>There are a variety of consequences of hormonal therapy in transgender men  (<a class="graphic graphic_table graphicRef75101" href="/z/d/graphic/75101.html" rel="external">table 3</a>). <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> causes male-pattern hair growth and an increase in lean body mass, muscle mass, and fat mass. It also causes growth in midline structures like the larynx and the clitoris (which may be associated with an increase in sexual desire).</p><p class="bulletIndent1"><span class="glyph">●</span>Hair – The development of sexual hair follows the pattern observed in pubertal boys: first the upper lip, then chin, then cheeks, etc [<a href="#rid20">20,21</a>]. The degree of hair growth might be predicted from the pattern in male members of the same family. The same applies to the occurrence of androgenetic alopecia, "male-pattern baldness."</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Voice – Deepening of the voice may occur due to oropharyngeal growth and may be irreversible [<a href="#rid22">22,23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Body composition – Androgen administration leads to a reduction in subcutaneous fat but increases in abdominal fat [<a href="#rid24">24</a>]. The increase in lean body mass is on average 4 kg, and the increase in body weight may be greater [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acne – Acne occurs in approximately 40 percent, similar to that observed in hypogonadal men starting androgen treatment past the age of normal puberty [<a href="#rid20">20,21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clitoral enlargement – Clitoral enlargement occurs in all, but the degree varies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sexual desire – Most subjects will note an increase in sexual desire [<a href="#rid26">26-28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Breasts – Androgen administration may cause a decrease in glandular tissue [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Guidelines have suggested hysterectomy to avoid cancer risk from endometrial exposure to androgen [<a href="#rid11">11</a>]. However, there is no evidence for an excess risk of endometrial cancer in transgender men receiving androgen therapy. In one trial of 35 transgender men receiving <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> undecanoate 1000 mg every 12 weeks for one year, mean endometrial thickness (on pelvic ultrasound) decreased from 9.9 to 5.7 mm [<a href="#rid26">26</a>]. In a second study, histologic analysis found inactive, atrophic endometrium in transgender men taking long-term testosterone therapy, similar to that seen in postmenopausal biological women not taking estrogen therapy [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The relatively lower height and the broader hip configuration of transgender men compared with nontransgender men does not change with <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> treatment.</p><p></p><p class="headingAnchor" id="H404502146"><span class="h4">Routine monitoring</span><span class="headingEndMark"> — </span>We agree with the monitoring schedule recommended by the Endocrine Society: Evaluate the patient every three months in the first year corresponding to dose adjustment and then one to two times per year thereafter  (<a class="graphic graphic_table graphicRef78811" href="/z/d/graphic/78811.html" rel="external">table 4</a>).</p><p>Serum <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> concentrations should be maintained in the physiologic range for men; endocrine monitoring should include serum testosterone, with goals of maintaining serum concentrations approximately 400 to 800 ng/dL (13.9 to 27.7 nmol/L). For patients on testosterone injections, trough levels should be towards the lower end of this range, while peak levels should not exceed 1000 ng/dL (34.7 nmol/L). Individuals taking testosterone gels should have similar targets, but the serum testosterone levels achieved tend to be at the lower end of the normal range. Serum estradiol is monitored during the first six months of testosterone treatment or until there has been no uterine bleeding for six months. Estradiol levels should be &lt;50 pg/mL (184 pmol/L)  (<a class="graphic graphic_table graphicRef78811" href="/z/d/graphic/78811.html" rel="external">table 4</a>).</p><p>In addition to monitoring weight and blood pressure, lab testing should include a hematocrit because erythrocytosis is a common consequence of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> administration, reported more with testosterone ester injections. Details of biochemical testing, bone mineral density (BMD) testing, and need for mammograms are outlined in the table  (<a class="graphic graphic_table graphicRef78811" href="/z/d/graphic/78811.html" rel="external">table 4</a>). (See <a class="local">'Adverse events'</a> below.)</p><p>Cancer screening is reviewed in detail separately. Briefly, transgender men who have undergone mastectomy do not require mammograms [<a href="#rid31">31</a>], but breast self-exam may still be important for appropriate surveillance. However, if mastectomy is delayed or not performed, mammography should be performed as for females in general. In addition, pap smears should be performed in transgender men who have cervical tissue present  (<a class="graphic graphic_table graphicRef102596" href="/z/d/graphic/102596.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/z/d/html/82964.html" rel="external">"Primary care of transgender individuals", section on 'Screening/preventive care'</a>.)</p><p class="headingAnchor" id="H4105974929"><span class="h4">Adverse events</span><span class="headingEndMark"> — </span>Androgen therapy is safe for most patients [<a href="#rid30">30,32</a>]. However, there are some potential adverse events.</p><p class="headingAnchor" id="H2814589455"><span class="h5">Persistent bleeding</span><span class="headingEndMark"> — </span>Menses usually stop within a few months of starting <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> [<a href="#rid33">33</a>]. However, in some individuals, bleeding may continue. Our approach is to increase the testosterone dose modestly. Another approach is to add an oral progestin such as <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (MPA; 5 to 10 mg daily continuously) or treatment with a gonadotropin-releasing hormone (GnRH) agonist to stop the menstrual bleeding [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H2265105513"><span class="h5">Metabolic</span><span class="headingEndMark"> — </span>The most commonly observed consequence of androgen therapy is erythrocytosis. We agree with the Endocrine Society and suggest that men receiving androgen therapy be monitored to keep the hematocrit less than 50 percent  (<a class="graphic graphic_table graphicRef78811" href="/z/d/graphic/78811.html" rel="external">table 4</a>). Lipid changes may necessitate intervention [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H4015397610"><span class="h5">Heart disease</span><span class="headingEndMark"> — </span>As described above, the effects of androgens on transgender men on biochemical risk markers are somewhat mixed [<a href="#rid34">34</a>]. A meta-analysis of 16 studies concluded that cross-sex hormone therapies increase serum triglycerides in both transgender women and transgender men [<a href="#rid35">35</a>]. However, data about patient-important outcomes such as atherosclerosis were limited and inconclusive. In spite of limited data, transgender persons treated with hormones should be evaluated for cardiovascular risk factors [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/82964.html" rel="external">"Primary care of transgender individuals", section on 'Cardiovascular disease'</a> and  <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H1517656230"><span class="h2">Fertility considerations</span><span class="headingEndMark"> — </span>Transgender individuals who take hormone therapy may limit fertility potential unless hormones are stopped. Individuals who undergo transgender genital surgery that includes loss of gonads lose their reproductive potential altogether. Thus, before starting any treatment, patients should be encouraged to consider fertility issues.</p><p>Transgender men may consider cryopreservation of oocytes or embryos [<a href="#rid36">36,37</a>]. While these options may provide preservation of fertility, the associated costs are high, particularly for cryopreservation of oocytes or embryos, which requires ovarian stimulation and oocyte retrieval in addition to storage fees. (See  <a class="medical medical_review" href="/z/d/html/7440.html" rel="external">"Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery", section on 'Fertility preservation'</a> and  <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions"</a>.)</p><p class="headingAnchor" id="H4293152276"><span class="h1">GENDER CONFIRMATION SURGERY</span><span class="headingEndMark"> — </span>Gender confirmation surgery (also referred to as gender-affirming surgery) is often the last (and most considered) step in the treatment process. Individuals can and do live successfully in their preferred gender role without genital surgery.</p><p>The criteria for initiating <strong>genital</strong> surgical treatment include the <strong>same criteria for hormone therapy</strong>, but an <strong>additional criterion</strong> is added due to its increased invasiveness [<a href="#rid1">1</a>] (see <a class="local">'Criteria for starting'</a> above):</p><p><strong>One year of continuous hormone therapy and living in the desired gender role</strong> is expected, unless it has been determined the hormone therapy is not medically indicated. This criterion is <strong>not</strong> required for surgeries like chest reconstruction or other nongenital surgeries.</p><p>Additional details for surgical procedures are available in the World Professional Association for Transgender Health (WPATH) Standards of Care [<a href="#rid1">1</a>]. (See <a class="local">'Standards of care'</a> above.)</p><p>Prior to surgery, the clinician should continue to counsel the patient to acknowledge the limitations of what gender confirmation surgery can achieve. In addition, the patient should continue to work closely with the supporting medical and mental health providers as appropriate.</p><p>The most commonly desired gender confirmation surgery for transgender men is chest reconstruction surgery (breast reduction [<a href="#rid38">38</a>]). Note that surgeons experienced with this surgery for men should be sought out (similar to men with gynecomastia in general).</p><p>For some transgender men, oophorectomy, hysterectomy, and/or vaginectomy may be considered after one to two years of androgen therapy, although practice patterns vary [<a href="#rid11">11</a>].</p><p>Genital reconstruction procedures are best performed in the few centers with specialized expertise. The surgeries can be less popular because of their cost and relatively high morbidity. One option is creation of a neophallus [<a href="#rid11">11,39</a>]. In other cases, a metaidoioplasty may be performed [<a href="#rid39">39,40</a>]. With this technique, the urethra is lengthened using an anterior vaginal wall flap to reach the tip of the phallic glans, and the clitoris is partially released and stretched by resection of the ventral chordae. From the labia majora, a scrotum can be constructed in which testicular prostheses can be implanted. This surgical intervention allows the patient to urinate standing. Alternatively, free flaps removed from arms or legs can be used to construct a neophallus.</p><p class="headingAnchor" id="H1101838365"><span class="h2">Sexual function after genital reconstruction surgery</span><span class="headingEndMark"> — </span>Little attention has been given to this subject, and research has been based on self-reports. As expected for those transgender men with a neophallus, there is a correlation between sexual function and the quality of the neophallus [<a href="#rid41">41</a>]. While not all transgender persons are orgasmic after a neophallus is created, many report sexual satisfaction [<a href="#rid27">27,42-44</a>]. Transgender men receiving androgens generally report an increase in sexual interest [<a href="#rid45">45</a>]. Systematic investigation is needed to gain more insight [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H699213379"><span class="h2">Regrets after gender confirmation surgery</span><span class="headingEndMark"> — </span>Given the irreversibility of gender confirmation surgery and, to a lesser degree, of cross-sex hormone administration, it would be desirable to have insight into factors that predict success or failure. Although regrets are rare, they do occur. Regrets are seen more often in those with difficulty in transitioning their appearance or limited social skills [<a href="#rid42">42,46</a>].</p><p class="headingAnchor" id="H176170841"><span class="h1">PSYCHOSOCIAL OUTCOMES OF TREATMENT</span><span class="headingEndMark"> — </span>Transgender treatment that includes hormonal therapy results in significant improvement in quality-of-life and psychosocial outcomes [<a href="#rid47">47</a>]. This was illustrated in a meta-analysis of 28 studies that enrolled 1833 transgender individuals (1093 transgender women, 801 transgender men) who underwent transgender treatment that included hormones [<a href="#rid42">42</a>]. In the pooled analysis, the percentage of patients reporting improvements in symptoms included:</p><p class="bulletIndent1"><span class="glyph">●</span>Gender dysphoria – 80 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Psychological symptoms – 78 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Quality of life – 80 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Sexual function – 72 percent</p><p></p><p class="headingAnchor" id="H3022567989"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117789.html" rel="external">"Society guideline links: Transgender health"</a>.)</p><p class="headingAnchor" id="H4145281116"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/86378.html" rel="external">"Patient education: Being transgender (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1195732673"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Transgender is an umbrella term that is used to describe individuals with gender diversity; it includes individuals whose gender identity is different from their sex recorded at birth. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transgender individuals should have their gender incongruence diagnosed by medical professionals with appropriate experience. It is necessary to ascertain that there is persistent gender incongruence and that the person is able to understand the risks and benefits of intervention. (See <a class="local">'Evaluation and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Before initiating transgender hormonal or surgical treatment, the clinician should counsel the patient about risks and benefits of the hormonal or surgical therapy, including impact on fertility, as well as realistic expectations about outcomes. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For transgender men (female-to-male [FTM]), we suggest either <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> esters (administered intramuscularly or subcutaneously) or testosterone gels, depending upon patient preference  (<a class="graphic graphic_table graphicRef69460" href="/z/d/graphic/69460.html" rel="external">table 2</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, higher testosterone levels are more easily achieved with parenteral therapy. (See <a class="local">'Testosterone therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transgender men who have undergone mastectomy do not require mammograms but may benefit from continued chest self-exam. However, if mastectomy is delayed or not performed, mammography should be performed as for females in general. In addition, pap smears should be performed in transgender men who have cervical tissue present  (<a class="graphic graphic_table graphicRef102596" href="/z/d/graphic/102596.html" rel="external">table 5</a>). (See <a class="local">'Routine monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest that transgender men receiving <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> therapy be monitored for erythrocytosis and dyslipidemia, two potential consequences of androgen therapy  (<a class="graphic graphic_table graphicRef78811" href="/z/d/graphic/78811.html" rel="external">table 4</a>). (See <a class="local">'Metabolic'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although they are not as popular as chest reconstruction surgeries, gender confirmation (or affirmation) genital and gonad-removing surgeries can be considered after living one year in the desired gender role and after one year of continuous hormone therapy (unless there a medical contraindication to hormone therapy). This criterion is specific to genital and gonad removing surgeries but <strong>not</strong> to other procedures such as chest reconstruction surgeries. Details of surgery are described above. (See <a class="local">'Gender confirmation surgery'</a> above.)</p><p></p><p class="headingAnchor" id="H2478872070"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate would like to acknowledge Louis JG Gooren, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgend 2012; 13:165.</a></li><li><a class="nounderline abstract_t">Nolan BJ, Leemaqz SY, Ooi O, et al. Prevalence of polycythaemia with different formulations of testosterone therapy in transmasculine individuals. Intern Med J 2021; 51:873.</a></li><li><a class="nounderline abstract_t">Taub RL, Ellis SA, Neal-Perry G, et al. The effect of testosterone on ovulatory function in transmasculine individuals. Am J Obstet Gynecol 2020; 223:229.e1.</a></li><li><a class="nounderline abstract_t">Krempasky C, Harris M, Abern L, Grimstad F. Contraception across the transmasculine spectrum. Am J Obstet Gynecol 2020; 222:134.</a></li><li><a class="nounderline abstract_t">Boudreau D, Mukerjee R. Contraception Care for Transmasculine Individuals on Testosterone Therapy. J Midwifery Womens Health 2019; 64:395.</a></li><li><a class="nounderline abstract_t">Libman H, Safer JD, Siegel JR, Reynolds EE. Caring for the Transgender Patient: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Ann Intern Med 2020; 172:202.</a></li><li><a class="nounderline abstract_t">Safer JD, Tangpricha V. Care of Transgender Persons. N Engl J Med 2019; 381:2451.</a></li><li><a class="nounderline abstract_t">Coleman E, Radix AE, Bouman WP, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgend Health 2022; 23:S1.</a></li><li><a class="nounderline abstract_t">Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2017; 102:3869.</a></li><li class="breakAll">http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Health-Care-for-Underserved-Women/Health-Care-for-Transgender-Individuals (Accessed on August 03, 2016).</li><li><a class="nounderline abstract_t">Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132.</a></li><li class="breakAll">World Professional Association for Transgender Health. Standards of care for gender identity disorders. http://wpath.org/publications_standards.cfm (Accessed on September 13, 2011).</li><li class="breakAll">American Psychiatric Association. Gender dysphoria. In: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, American Psychiatric Association, Arlington, VA 2013. p.451.</li><li><a class="nounderline abstract_t">Gooren L. Hormone treatment of the adult transsexual patient. Horm Res 2005; 64 Suppl 2:31.</a></li><li><a class="nounderline abstract_t">Becerra Fernández A, de Luis Román DA, Piédrola Maroto G. [Morbidity in transsexual patients with cross-gender hormone self-treatment]. Med Clin (Barc) 1999; 113:484.</a></li><li><a class="nounderline abstract_t">Olson J, Schrager SM, Clark LF, et al. Subcutaneous Testosterone: An Effective Delivery Mechanism for Masculinizing Young Transgender Men. LGBT Health 2014; 1:165.</a></li><li><a class="nounderline abstract_t">McFarland J, Craig W, Clarke NJ, Spratt DI. Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone. J Endocr Soc 2017; 1:1095.</a></li><li><a class="nounderline abstract_t">Spratt DI, Stewart II, Savage C, et al. Subcutaneous Injection of Testosterone Is an Effective and Preferred Alternative to Intramuscular Injection: Demonstration in Female-to-Male Transgender Patients. J Clin Endocrinol Metab 2017; 102:2349.</a></li><li><a class="nounderline abstract_t">Dobs AS, McGettigan J, Norwood P, et al. A novel testosterone 2% gel for the treatment of hypogonadal males. J Androl 2012; 33:601.</a></li><li><a class="nounderline abstract_t">Giltay EJ, Gooren LJ. Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab 2000; 85:2913.</a></li><li><a class="nounderline abstract_t">Wierckx K, Van de Peer F, Verhaeghe E, et al. Short- and long-term clinical skin effects of testosterone treatment in trans men. J Sex Med 2014; 11:222.</a></li><li><a class="nounderline abstract_t">Gooren LJ, Giltay EJ. Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. J Sex Med 2008; 5:765.</a></li><li><a class="nounderline abstract_t">Cosyns M, Van Borsel J, Wierckx K, et al. Voice in female-to-male transsexual persons after long-term androgen therapy. Laryngoscope 2014; 124:1409.</a></li><li><a class="nounderline abstract_t">Lapauw B, Taes Y, Simoens S, et al. Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone 2008; 43:1016.</a></li><li><a class="nounderline abstract_t">Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 2008; 93:19.</a></li><li><a class="nounderline abstract_t">Mueller A, Kiesewetter F, Binder H, et al. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. J Clin Endocrinol Metab 2007; 92:3470.</a></li><li><a class="nounderline abstract_t">Wierckx K, Elaut E, Van Caenegem E, et al. Sexual desire in female-to-male transsexual persons: exploration of the role of testosterone administration. Eur J Endocrinol 2011; 165:331.</a></li><li><a class="nounderline abstract_t">Costantino A, Cerpolini S, Alvisi S, et al. A prospective study on sexual function and mood in female-to-male transsexuals during testosterone administration and after sex reassignment surgery. J Sex Marital Ther 2013; 39:321.</a></li><li><a class="nounderline abstract_t">Slagter MH, Gooren LJ, Scorilas A, et al. Effects of long-term androgen administration on breast tissue of female-to-male transsexuals. J Histochem Cytochem 2006; 54:905.</a></li><li><a class="nounderline abstract_t">Perrone AM, Cerpolini S, Maria Salfi NC, et al. Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals. J Sex Med 2009; 6:3193.</a></li><li><a class="nounderline abstract_t">Gooren LJ, van Trotsenburg MA, Giltay EJ, van Diest PJ. Breast cancer development in transsexual subjects receiving cross-sex hormone treatment. J Sex Med 2013; 10:3129.</a></li><li><a class="nounderline abstract_t">Weinand JD, Safer JD. Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals. J Clin Transl Endocrinol 2015; 2:55.</a></li><li><a class="nounderline abstract_t">Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab 2003; 88:3467.</a></li><li><a class="nounderline abstract_t">Elbers JM, Giltay EJ, Teerlink T, et al. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf) 2003; 58:562.</a></li><li><a class="nounderline abstract_t">Elamin MB, Garcia MZ, Murad MH, et al. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clin Endocrinol (Oxf) 2010; 72:1.</a></li><li><a class="nounderline abstract_t">De Sutter P. Gender reassignment and assisted reproduction: present and future reproductive options for transsexual people. Hum Reprod 2001; 16:612.</a></li><li><a class="nounderline abstract_t">Wierckx K, Van Caenegem E, Pennings G, et al. Reproductive wish in transsexual men. Hum Reprod 2012; 27:483.</a></li><li><a class="nounderline abstract_t">Kailas M, Lu HMS, Rothman EF, Safer JD. PREVALENCE AND TYPES OF GENDER-AFFIRMING SURGERY AMONG A SAMPLE OF TRANSGENDER ENDOCRINOLOGY PATIENTS PRIOR TO STATE EXPANSION OF INSURANCE COVERAGE. Endocr Pract 2017; 23:780.</a></li><li><a class="nounderline abstract_t">Monstrey SJ, Ceulemans P, Hoebeke P. Sex Reassignment Surgery in the Female-to-Male Transsexual. Semin Plast Surg 2011; 25:229.</a></li><li><a class="nounderline abstract_t">Hage JJ. Metaidoioplasty: an alternative phalloplasty technique in transsexuals. Plast Reconstr Surg 1996; 97:161.</a></li><li><a class="nounderline abstract_t">Green R. Sexual functioning in post-operative transsexuals: male-to-female and female-to-male. Int J Impot Res 1998; 10 Suppl 1:S22.</a></li><li><a class="nounderline abstract_t">Murad MH, Elamin MB, Garcia MZ, et al. Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes. Clin Endocrinol (Oxf) 2010; 72:214.</a></li><li><a class="nounderline abstract_t">Klein C, Gorzalka BB. Sexual functioning in transsexuals following hormone therapy and genital surgery: a review. J Sex Med 2009; 6:2922.</a></li><li><a class="nounderline abstract_t">Wierckx K, Van Caenegem E, Elaut E, et al. Quality of life and sexual health after sex reassignment surgery in transsexual men. J Sex Med 2011; 8:3379.</a></li><li><a class="nounderline abstract_t">Wierckx K, Elaut E, Van Hoorde B, et al. Sexual desire in trans persons: associations with sex reassignment treatment. J Sex Med 2014; 11:107.</a></li><li><a class="nounderline abstract_t">Weyers S, Elaut E, De Sutter P, et al. Long-term assessment of the physical, mental, and sexual health among transsexual women. J Sex Med 2009; 6:752.</a></li><li><a class="nounderline abstract_t">Fisher AD, Castellini G, Ristori J, et al. Cross-Sex Hormone Treatment and Psychobiological Changes in Transsexual Persons: Two-Year Follow-Up Data. J Clin Endocrinol Metab 2016; 101:4260.</a></li></ol></div><div id="topicVersionRevision">Topic 109911 Version 11.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32237098" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevalence of polycythaemia with different formulations of testosterone therapy in transmasculine individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32044312" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The effect of testosterone on ovulatory function in transmasculine individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31394072" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Contraception across the transmasculine spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30997955" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Contraception Care for Transmasculine Individuals on Testosterone Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32016334" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Caring for the Transgender Patient: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31851801" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Care of Transgender Persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36238954" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Standards of Care for the Health of Transgender and Gender Diverse People, Version 8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28945902" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28945902" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19509099" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19509099" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19509099" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16286768" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hormone treatment of the adult transsexual patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10604171" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : [Morbidity in transsexual patients with cross-gender hormone self-treatment].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26789709" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Subcutaneous Testosterone: An Effective Delivery Mechanism for Masculinizing Young Transgender Men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29264562" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28379417" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Subcutaneous Injection of Testosterone Is an Effective and Preferred Alternative to Intramuscular Injection: Demonstration in Female-to-Male Transgender Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21979302" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A novel testosterone 2% gel for the treatment of hypogonadal males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10946903" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24344810" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Short- and long-term clinical skin effects of testosterone treatment in trans men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17971101" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24155064" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Voice in female-to-male transsexual persons after long-term androgen therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18835591" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Body composition, volumetric and areal bone parameters in male-to-female transsexual persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17986639" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17579193" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21602316" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Sexual desire in female-to-male transsexual persons: exploration of the role of testosterone administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23470169" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A prospective study on sexual function and mood in female-to-male transsexuals during testosterone administration and after sex reassignment surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16618941" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effects of long-term androgen administration on breast tissue of female-to-male transsexuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19570144" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24010586" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Breast cancer development in transsexual subjects receiving cross-sex hormone treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28090436" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12915619" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12699437" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19473174" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11278204" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Gender reassignment and assisted reproduction: present and future reproductive options for transsexual people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22128292" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Reproductive wish in transsexual men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28448757" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : PREVALENCE AND TYPES OF GENDER-AFFIRMING SURGERY AMONG A SAMPLE OF TRANSGENDER ENDOCRINOLOGY PATIENTS PRIOR TO STATE EXPANSION OF INSURANCE COVERAGE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22851915" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sex Reassignment Surgery in the Female-to-Male Transsexual.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8532774" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Metaidoioplasty: an alternative phalloplasty technique in transsexuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9669217" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Sexual functioning in post-operative transsexuals: male-to-female and female-to-male.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19473181" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20092545" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Sexual functioning in transsexuals following hormone therapy and genital surgery: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21699661" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Quality of life and sexual health after sex reassignment surgery in transsexual men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24165564" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Sexual desire in trans persons: associations with sex reassignment treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19040622" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Long-term assessment of the physical, mental, and sexual health among transsexual women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27700538" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cross-Sex Hormone Treatment and Psychobiological Changes in Transsexual Persons: Two-Year Follow-Up Data.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
